Common Contracts
3 similar Merger Agreement contracts by Adaptimmune Therapeutics PLC, Akari Therapeutics PLC, Peak Bio, Inc.
AGREEMENT AND PLAN OF MERGERMerger Agreement • March 5th, 2024 • Peak Bio, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 4, 2024, is among Akari Therapeutics, Plc (“Parent”), a public company limited by shares incorporated in England and Wales, Pegasus Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and a wholly owned subsidiary of Parent, and Peak Bio, Inc. (the “Company”), a Delaware corporation.
AGREEMENT AND PLAN OF MERGER BY AND AmONG AKARI THERAPEUTICS, PLC, PEGASUS MERGER SUB, INC. AND PEAK BIO, INC. Dated as of March 4, 2024Merger Agreement • March 5th, 2024 • Akari Therapeutics PLC • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 4, 2024, is among Akari Therapeutics, Plc (“Parent”), a public company limited by shares incorporated in England and Wales, Pegasus Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and a wholly owned subsidiary of Parent, and Peak Bio, Inc. (the “Company”), a Delaware corporation.
AGREEMENT AND PLAN OF MERGER BY AND AmONG Adaptimmune therapeutics plc, AND tcr2 therapeutics inc. Dated as of March 5, 2023Merger Agreement • March 6th, 2023 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 5, 2023, is among Adaptimmune Therapeutics plc (“Parent”), a public limited company incorporated in England and Wales, CM Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and an indirect wholly-owned subsidiary of Parent, and TCR2 Therapeutics Inc. (the “Company”), a Delaware corporation.
